Targeting PD-1/PD-L1 in lung cancer: current perspectives

María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit,...

Full description

Bibliographic Details
Main Authors: González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R
Format: Article
Language:English
Published: Dove Medical Press 2015-07-01
Series:Lung Cancer : Targets and Therapy
Online Access:http://www.dovepress.com/targeting-pd-1pd-l1-in-lung-cancer-current-perspectives-peer-reviewed-article-LCTT
id doaj-53cb1147aa7d460ab1939a5683d7eba4
record_format Article
spelling doaj-53cb1147aa7d460ab1939a5683d7eba42020-11-24T22:45:20ZengDove Medical PressLung Cancer : Targets and Therapy1179-27282015-07-012015default557022925Targeting PD-1/PD-L1 in lung cancer: current perspectivesGonzález-Cao MKarachaliou NViteri SMorales-Espinosa DTeixidó CSánchez Ruiz JMolina-Vila MÁSantarpia MRosell RMaría González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; 2Pangaea Biotech SL, Barcelona, Spain; 3Centro Nacional de Investigación Oncología (CNIO), Madrid, Spain; 4Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy; 5Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; 6Fundación Molecular Oncology Research, Barcelona, SpainAbstract: Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I–III trials with anti-PD-1/PD-L1 antibodies in non-small-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.Keywords: immunotherapy, immunoncology, cancer, checkpoint inhibitorshttp://www.dovepress.com/targeting-pd-1pd-l1-in-lung-cancer-current-perspectives-peer-reviewed-article-LCTT
collection DOAJ
language English
format Article
sources DOAJ
author González-Cao M
Karachaliou N
Viteri S
Morales-Espinosa D
Teixidó C
Sánchez Ruiz J
Molina-Vila MÁ
Santarpia M
Rosell R
spellingShingle González-Cao M
Karachaliou N
Viteri S
Morales-Espinosa D
Teixidó C
Sánchez Ruiz J
Molina-Vila MÁ
Santarpia M
Rosell R
Targeting PD-1/PD-L1 in lung cancer: current perspectives
Lung Cancer : Targets and Therapy
author_facet González-Cao M
Karachaliou N
Viteri S
Morales-Espinosa D
Teixidó C
Sánchez Ruiz J
Molina-Vila MÁ
Santarpia M
Rosell R
author_sort González-Cao M
title Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_short Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_full Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_fullStr Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_full_unstemmed Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_sort targeting pd-1/pd-l1 in lung cancer: current perspectives
publisher Dove Medical Press
series Lung Cancer : Targets and Therapy
issn 1179-2728
publishDate 2015-07-01
description María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; 2Pangaea Biotech SL, Barcelona, Spain; 3Centro Nacional de Investigación Oncología (CNIO), Madrid, Spain; 4Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy; 5Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; 6Fundación Molecular Oncology Research, Barcelona, SpainAbstract: Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I–III trials with anti-PD-1/PD-L1 antibodies in non-small-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.Keywords: immunotherapy, immunoncology, cancer, checkpoint inhibitors
url http://www.dovepress.com/targeting-pd-1pd-l1-in-lung-cancer-current-perspectives-peer-reviewed-article-LCTT
work_keys_str_mv AT gonzaacutelezcaom targetingpd1pdl1inlungcancercurrentperspectives
AT karachalioun targetingpd1pdl1inlungcancercurrentperspectives
AT viteris targetingpd1pdl1inlungcancercurrentperspectives
AT moralesespinosad targetingpd1pdl1inlungcancercurrentperspectives
AT teixidoacutec targetingpd1pdl1inlungcancercurrentperspectives
AT saacutenchezruizj targetingpd1pdl1inlungcancercurrentperspectives
AT molinavilamaacute targetingpd1pdl1inlungcancercurrentperspectives
AT santarpiam targetingpd1pdl1inlungcancercurrentperspectives
AT rosellr targetingpd1pdl1inlungcancercurrentperspectives
_version_ 1725689000810774528